Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Current Liabilities (2016 - 2025)

Assembly Biosciences has reported Total Current Liabilities over the past 11 years, most recently at $48.8 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $48.8 million for Q4 2025, up 2.04% from a year ago — trailing twelve months through Dec 2025 was $48.8 million (up 2.04% YoY), and the annual figure for FY2025 was $48.8 million, up 2.04%.
  • Total Current Liabilities for Q4 2025 was $48.8 million at Assembly Biosciences, down from $53.4 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ASMB hit a ceiling of $53.4 million in Q3 2025 and a floor of $7.1 million in Q3 2023.
  • Median Total Current Liabilities over the past 5 years was $16.2 million (2021), compared with a mean of $27.4 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 53.87% in 2023 and later skyrocketed 483.78% in 2024.
  • Assembly Biosciences' Total Current Liabilities stood at $16.1 million in 2021, then increased by 1.39% to $16.3 million in 2022, then surged by 140.7% to $39.2 million in 2023, then increased by 21.87% to $47.8 million in 2024, then increased by 2.04% to $48.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $48.8 million (Q4 2025), $53.4 million (Q3 2025), and $47.3 million (Q2 2025) per Business Quant data.